Efficacy and safety of hepatitis C antiviral therapy in moderate and severe chronic kidney disease

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Indian Journal of Gastroenterology

• Publication date

  2014-07-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12664-014-0487-6PMID 25015745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline

  2013cited by this paper
• Pegylated Interferon-α2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis

  2013cited by this paper
• Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis

  2013cited by this paper
• Hepatitis C Infection Is Very Rarely Treated among Hemodialysis Patients

  2013cited by this paper
• Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre.

  2012influential reference
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2011cited by this paper
• Anti‐viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy

  2011cited by this paper
• Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital

  2009cited by this paper
• Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.

  2008cited by this paper
• Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.

  2008influential reference
• Pegylated interferon α-2a versus standard interferon α-2a for treatment-naïve dialysis patients with chronic hepatitis C: a randomised study

  2007cited by this paper
• Interferon monotherapy of chronic hepatitis C in dialysis patients: meta‐analysis of clinical trials

  2007influential reference
• Meta‐analysis: anti‐viral therapy of hepatitis C virus‐related liver disease in renal transplant patients

  2006cited by this paper
• Meta‐analysis: effect of hepatitis C virus infection on mortality in dialysis

  2004cited by this paper
• Renal transplantation offers a better survival in HCV‐infected ESRD patients

  2004cited by this paper
• Diversity of Hepatitis C Virus Quasispecies Evaluated by Denaturing Gradient Gel Electrophoresis

  2001cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Impact of hepatitis B and C virus on kidney transplantation outcome

  1999cited by this paper
• Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.

  1998cited by this paper

• No citing papers are available for this paper.